Viz.ai announced today that it entered into a multi-year agreement with Bristol Myers Squibb (NYSE:BMY) for detecting hypertrophic cardiomyopathy.
The partnership seeks to deploy an AI algorithm and the Viz HCM provider workflow software. This can help identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy.
San Francisco-based Viz.ai submitted a de novo request to the FDA for the algorithm as a software-as-a-medical device (SaMD). The agency accepted the filing for review, according to a news release.
Hypertrophic cardiomyopathy (HCM) occurs when heart muscle thickens, making it harder for the heart to pump blood. It can lead to increased risks of AFib, mitral valve disease and heart failure.
Suhas Krishna, Bristol Myers Squibb VP and head of digital health product management, said the company believes AI can positively impact patients’ lives by detecting key, subtle characteristics i…